Table 2.
Comparison of mutational frequency in MS with reported data
| MS series (n = 13) | AML (n = 188) | p | OR (95% CI) | AML (n = 1540) | p | OR (95% CI) | |
|---|---|---|---|---|---|---|---|
| NRAS | 4 (30.8%) | 15 (8.0%) | 0.024 | 5.06 (1.017–21.003) | 270 (17.5%) | 0.263 | 2.09 (0.467–7.553) |
| FLT3 ITD | 2 (15.4%) | 54 (28.7%) | 0.522 | 0.45 (0.047–2.178) | 521 (33.8%) | 0.240 | .36 (0.038–1.639) |
| KIT | 2 (15.4%) | 7 (3.7%) | 0.108 | 4.64 (0.423–28.704) | 66 (4.3%) | 0.108 | 4.05 (0.428–19.139) |
| KRAS | 2 (15.4%) | 8 (4.3%) | 0.130 | 4.04 (0.375–24.053) | 79 (6.8%) | 0.145 | 3.36 (0.356–15.783) |
| JAK2 | 1 (7.7%) | 1 (0.5%) | 0.126 | 15.01 (0.183–1215.0) | 11 (0.7%) | 0.096 | 11.52 (0.249–92.017) |
| ERBB2 | 1 (7.7%) | 0 | 0.065 | NA (0.371–NA) | NA | NA | NA |
| PIK3CA | 1 (7.7%) | 0 | 0.065 | NA (0.371–NA) | NA | NA | NA |
| RET | 1 (7.7%) | 0 | 0.065 | NA (0.371–NA) | NA | NA | NA |
| RTK-RAS genes | 11 (84.6%) | 81 (43.1%) | 0.007 | 7.20 (1.510–68.768) | 841 (54.6%) | 0.046 | 4.57 (0.992–42.492) |
| GNAQ | 2 (15.4%) | 0 | 0.004 | NA (2.839–NA) | NA | NA | NA |
| STK11 | 1 (7.7%) | 0 | 0.065 | NA (0.371–NA) | NA | NA | NA |
| IDH2 | 3 (23.1%) | 19 (10.1%) | 0.157 | 2.65 (0.432–11.569) | 108 (7.5%) | 0.060 | 3.97 (0.692–15.730) |
| NPM1 | 2 (15.4%) | 52 (27.7%) | 0.520 | 0.477 (0.050–2.297) | 440 (28.6%) | 0.371 | 0.455 (0.049–2.096) |
MS myeloid sarcoma, AML acute myeloid leukemia, OR odds ratio, CI confidence interval, ITD internal tandem duplication, NA not applicable, RTK-RAS genes receptor tyrosine kinase-RAS pathway genes